PharmaShots | Incisive News in 3 Shots

Subscribe Now

Chronic Graft-Versus-Host Disease

Incyte Enters into an Exclusive WW License Agreement with Syndax to Develop and Commercialize Axatilimab for cGVHD and Other Fibrotic Diseases

Incyte Enters into an Exclusive WW License Agreement with Syndax to Develop and Commercialize Axatilimab for cGVHD and Other Fibro...

September 27, 2021

Incyte's Jakafi (ruxolitinib) Receives the US FDA's Approval for the Treatment of Chronic Graft-Versus-Host Disease

Incyte's Jakafi (ruxolitinib) Receives the US FDA's Approval for the Treatment of Chronic Graft-Versus-Host Disease

September 23, 2021

Incyte and Novartis Publish Results of Jakafi (ruxolitinib) in P-III REACH3 Study to Treat Chronic Graft-Versus-Host Disease in NEJM

Incyte and Novartis Publish Results of Jakafi (ruxolitinib) in P-III REACH3 Study to Treat Chronic Graft-Versus-Host Disease in NE...

July 15, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us